Showing 1791-1800 of 2002 results for "".
- New From Neocutis: Meet the Micro-Riche Linehttps://practicaldermatology.com/news/new-from-neocutis-meet-the-micro-riche-line/2458420/NEOCUTIS is rolling out a new line. The MICRO-RICHE ultra-hydrating line will expand the company’s MICRO-PROTEIN Complex (MPC) product line. The new MICRO-RICHE line includes more emollient versions of MICRO-NIGHT and MICRO-EYE to keep skin nourished and hydrated as winter approache
- Stelara Adds New Approval: Crohn's Diseasehttps://practicaldermatology.com/news/stelara-adds-new-approval-crohns-disease/2458422/The FDA has approved STELARA® (ustekinumab) from Janssen Biotech, Inc., for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticost
- Novan, Inc. Launches IPO, Lists on NASDAQhttps://practicaldermatology.com/news/novan-inc-launches-ipo-lists-on-nasdaq/2458429/Novan, Inc. (the “Company” or “Novan”) today announced the pricing of the Company’s initial public offering of 4,100,000 shares of common stock at a price to the public of $11.00 per share. The common stock of Novan has been approved for listing on the NASDAQ Global
- Venus Concept Unveils Venus Freeze Plus for Non-Invasive Anti-Aging Treatmentshttps://practicaldermatology.com/news/venus-concept-unveils-venus-freeze-plus-for-non-invasive-anti-aging-treatments/2458432/Venus Concept's non-invasive anti-aging device, Venus Freeze Plus, is now available in the US. It is indicated for the treatment of moderate-to-severe facial wrinkles and rhytides, leading to the tightening of the skin, with no pain or downtime. Venus Freeze Plus works by using Venus
- Allergan Bolsters Medical Derm Portfolio with Vitae Acquisitionhttps://practicaldermatology.com/news/allergan-to-acquire-vitae-pharmaceuticals/2458435/Allergan plc is acquiring Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company. The move will serve to bolster Allergan’s medical dermatology pipeline, with the addition of VTP-43742, a Phase 2 first-in-class, orally active ROR?t (retin
- Kybella for Men May Mean Buh-Bye Beardshttps://practicaldermatology.com/news/kybella-for-men-may-mean-buh-bye-beards/2458456/If Allergan’s double-chin melting injectable Kybella were to really take off among men, we may be seeing a lot fewer beards, jokes bearded Washington DC –based dermatologist Terrence Keaney, MD. Male aesthetics is a growing market,
- It's So Far, So Good for BioPharmX's New Acne Drughttps://practicaldermatology.com/news/its-so-far-so-good-for-biopharmxs-new-acne-drug/2458458/BioPharmX Corporation’s novel topical minocycline, BPX-01, reduced facial P. acnes by more than 90 percent after four weeks, new research shows. In the Phase 2a study, a daily 10 mg dose of topical minocycline offered P. acnes r
- Paratek Initiates Phase 3 Study of Oral Omadacycline for MRSA, Acute Skin Infectionshttps://practicaldermatology.com/news/paratek-initiates-phase-3-study-of-oral-omadacycline-for-mrsa-acute-skin-infections/2458465/The first patient has been dosed in Paratek Pharmaceuticals, Inc.’s second pivotal Phase 3 study of omadacycline for acute bacterial skin and skin structure infections (ABSSSI). Omadacycline is a new once-daily oral and IV, well-tolerated
- Meeting Pearls and More: Don't Miss DermTube's Summer AAD Coveragehttps://practicaldermatology.com/news/dont-miss-dermtubes-summer-aad-coverage/2458481/Don’t Miss DermTube’s upcoming coverage of the Summer American Academy of Dermatology (AAD) Meeting in Boston. Summer AAD takes place from July 28-31, 2016. Hosted by Seemal R. Desai, MD
- Dermatologist Todd Schlesinger to Host Bellafill Discussion Fridayhttps://practicaldermatology.com/news/dermatologist-todd-schlesinger-to-host-bellafill-discussion-friday/2458484/Todd E. Schlesinger, MD, FAAD will host a program on behalf of Suneva, in which he will discuss Suneva's Bellafill® and other products. The event will be held Friday, July 29th, 2016 at 8pm at Towne Stove and Spirits, 900 Boylston Street, Boston. Those interested in atte